Call for South Asian bone marrow donors to save four-year-old
Esha Nadeswaran from London has leukaemia and needs a stem cell donor to save her life. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 14, 2021 Category: Consumer Health News Source Type: news

Consumer Health: Childhood cancer
September is Childhood Cancer Awareness Month, which makes this a good time to learn about three of the most common types of cancers in children: acute lymphocytic leukemia, neuroblastoma and pediatric brain tumors. Acute lymphocytic leukemia Acute lymphocytic leukemia is a cancer of the blood and bone marrow. It's the most common type of cancer in children, and treatments result in a good chance for a cure. Acute lymphocytic leukemia also can occur in adults, though… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 6, 2021 Category: Databases & Libraries Source Type: news

Toddler diagnosed with cancer after rash found on his ankle - signs of leukaemia to spot
A TODDLER has been fighting cancer for three years after his mother found a mysterious rash on his ankle. Now his parents are urging others to look out for this potential sign of leukaemia. (Source: Daily Express - Health)
Source: Daily Express - Health - September 5, 2021 Category: Consumer Health News Source Type: news

Cancer symptoms: Two fruits have a 'strong protective effect against childhood leukaemia'
EVERY day in the UK, 12 children - and their carers - will receive the heart-breaking news that they have cancer. As September is Childhood Cancer Awareness Month, Express.co.uk are highlighting the latest research in this field. (Source: Daily Express - Health)
Source: Daily Express - Health - September 2, 2021 Category: Consumer Health News Source Type: news

Consumer Health: What do you know about leukemia and lymphoma?
September is Leukemia and Lymphoma Awareness Month, which makes this a good time to learn about some of the most common types of these two diseases. Leukemia is cancer of the body's blood-forming tissues, including bone marrow and the lymphatic system. Leukemia usually involves the white blood cells, which are potent infection fighters. They normally grow and divide in an orderly way as your body needs them. But in people with leukemia, the bone marrow… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 2, 2021 Category: Databases & Libraries Source Type: news

JCVI announces only 500,000 immunocompromised Brits should get Covid booster vaccines
Between 400,000 and 500,000 of the most vulnerable UK patients - including those with leukemia, HIV and organ transplant patients - will be made eligible for the top-up doses. (Source: the Mail online | Health)
Source: the Mail online | Health - September 1, 2021 Category: Consumer Health News Source Type: news

Blood cancer symptoms: The sign when you sleep that could signal the deadly disease
THERE are myriad symptoms to look out for when detecting the early stages of blood cancer. These indications differ when determining the nature of blood cancer, whether it is lymphoma, leukaemia myeloma, MDS, MPN or any other classification. However, recent studies have discovered an emerging symptom to look out for during the night. (Source: Daily Express - Health)
Source: Daily Express - Health - August 31, 2021 Category: Consumer Health News Source Type: news

'Symptoms were things you would see in a normal baby' Ashley Cain issues advice to parents
ASHLEY CAIN and Safiyya Vorajee spoke poignantly about the loss of their child Azaylia to acute myeloid leukemia on ITV'S Lorraine on Tuesday. Ashley issued important advice about the symptoms to spot in your child. (Source: Daily Express - Health)
Source: Daily Express - Health - August 31, 2021 Category: Consumer Health News Source Type: news

New Therapies Have Transformed Acute Lymphoblastic Leukemia Care New Therapies Have Transformed Acute Lymphoblastic Leukemia Care
Novel, chemotherapy-free regimens are poised to become standard of care in Philadelphia chromosome-positive acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 27, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Pharma built on Shire's old cancer business gets new FDA approval
Servier Pharmaceuticals, the Boston-based subsidiary of the French Servier Group that was built around Shire plc ’s cancer business, has scored an approval from the U.S. Food and Drug Administration for a cancer drug and a related diagnostic test. The FDA on Wednesday gave the go-ahead to a drug called Tibsovo, which is currently only used to treat a specific type of acute myeloid leukemia, to be used in a mutation-specific metastatic cholangiocarcinoma, a rare but aggressive cancer that attacks… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 26, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

Leukemia Quiz
Title: Leukemia QuizCategory: MedicineNet QuizCreated: 1/9/2012 5:47:00 PMLast Editorial Review: 8/26/2021 5:36:25 PM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 26, 2021 Category: Cancer & Oncology Source Type: news

Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
Chimeric antigen receptor (CAR)–modified T cell therapy is effective in treating lymphomas, leukemias, and multiple myeloma in which the tumor cells express high amounts of target antigen. However, achieving durable remission for these hematological malignancies and extending CAR T cell therapy to patients with solid tumors will require receptors that can recognize and eliminate tumor cells with a low density of target antigen. Although CARs were designed to mimic T cell receptor (TCR) signaling, TCRs are at least 100-fold more sensitive to antigen. To design a CAR with improved antigen sensitivity, we directly compa...
Source: Signal Transduction Knowledge Environment - August 24, 2021 Category: Science Authors: Salter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., Whiteaker, J. R., Gottardo, R., Veatch, S. L., Paulovich, A. G., Riddell, S. R. Tags: STKE Research Articles Source Type: news

BlueSphere Bio names board chair
Pittsburgh biotech firm BlueSphere Bio has named industry vet Jonathan Peacock as its board chair. BlueSphere Bio is developing T-cell therapies for leukemia and is also working on therapies for solid tumors. The firm recently finished a $105 million Series B round that was led by UPMC Enterprises.  Peacock is the former CFO of Amgen and is lead director of Avantor and is also a board member of Genmab and UCB. BlueSphere Bio said that Peacock and other moves will help the company build up its… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 19, 2021 Category: Biotechnology Authors: Paul J. Gough Source Type: news

Participant ’s Diagnosis Halts Gene Therapy Clinical Trial
The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia. (Source: The Scientist)
Source: The Scientist - August 12, 2021 Category: Science Tags: News & Opinion Source Type: news

St. Jude ’s Fundraising Chief on Space Missions, ‘Pushing Boundaries’ and a Record-Setting Year
St. Jude Children’s Research Hospital, which looks after children with cancer while also researching how to eliminate the pediatric form of the disease, raised $2 billion in donations in its last fiscal year. It’s a record for an independent charity, and an impressive feat in a year when donors had more causes than ever vying for their attention and money. Richard Shadyac, the CEO of the American Lebanese Syrian Associated Charities (St. Jude’s fundraising organization), attributes that success to a nimble pivot to different fundraising strategies—one of which was a collaboration with Inspiration4,...
Source: TIME: Science - August 10, 2021 Category: Science Authors: Belinda Luscombe Tags: Uncategorized Magazine Space Special Project Source Type: news

Why giving blood could help save cancer patients
Melody, 44, had suspected that her son Andrew Berthoud had chickenpox. It was acute lymphoblastic leukaemia and he needed chemotherapy and 22 blood transfusions. (Source: the Mail online | Health)
Source: the Mail online | Health - August 9, 2021 Category: Consumer Health News Source Type: news

Better CNS Control in Children With ALL:'Goldilocks' Approach Better CNS Control in Children With ALL:'Goldilocks' Approach
Treatment of central nervous system involvement in pediatric acute lymphoblastic leukemia needs to be based on risk, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 9, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous...
Source: Roche Media News - August 9, 2021 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous...
Source: Roche Investor Update - August 9, 2021 Category: Pharmaceuticals Source Type: news

Duration of Maintenance Therapy Studied in Childhood ALL
MONDAY, Aug. 2, 2021 -- For patients with low-risk childhood acute lymphoblastic leukemia, the omission of seven pulses of therapy with vincristine and oral dexamethasone during the second year of maintenance therapy might not worsen treatment... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 2, 2021 Category: Pharmaceuticals Source Type: news

Inotuzumab ozogamicin cost effective for acute lymphoblastic leukaemia in Sweden and Norway
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news

Eliminating RNA-binding protein improves survival in aggressive leukemia
Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer ’s development and significantly increase the likelihood of survival, according to a study in mice led by scientists at theUCLA Jonsson Comprehensive Cancer Center.The research,published today in the journal Leukemia, could aid in the development of targeted therapies for cancers that have high levels of the RNA-binding protein IGF2BP3 — especially acute lymphoblastic and myeloid leukemias that are characterized by chromosomal rearrangements in the mixed lineage leukemia (MLL) gene.In these ML...
Source: UCLA Newsroom: Health Sciences - July 29, 2021 Category: Universities & Medical Training Source Type: news

Racial Disparities Persist in Multiple Myeloma Care, Outcomes
MONDAY, July 26, 2021 -- There are persistent disparities in multiple myeloma (MM) care for non-Hispanic (NH)-Blacks and Hispanics compared with NH-Whites, according to a study published online July 18 in Leukemia& Lymphoma. Samer Al Hadidi,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 26, 2021 Category: Pharmaceuticals Source Type: news

Chemotherapy can induce mutations that lead to pediatric leukemia relapse
(St. Jude Children's Research Hospital) A collaboration led by St. Jude Children's Research Hospital, Shanghai Children's Medical Center and others revealed how thiopurines produce mutations that lead to multi-drug resistant leukemia and relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment for malignant pleural mesothelioma. The latest step was a clinical trial exploring a first-in-human, intrapleural-administered CAR T-cell therapy used in combination with pembrolizumab, a well-known immunotherapy drug also known by the brand name Keytruda. Results were impressive, including a 23.9-month median overall survival and an 83% one-year survival rate for patients. Cancer Discovery published the single-center study results July 15. “There is ...
Source: Asbestos and Mesothelioma News - July 22, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

Risk for Psoriasis Increased for Cancer Survivors
Increased risks seen for survivors of leukemia, lymphoma, multiple myeloma, skin cancer, and lung cancer in subgroup analyses (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 21, 2021 Category: Cancer & Oncology Tags: Dermatology, Internal Medicine, Oncology, Journal, Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Investor Update - July 21, 2021 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Media News - July 21, 2021 Category: Pharmaceuticals Source Type: news

Study: Ibrutinib effective treatment for difficult to treat forms of hairy cell leukemia
(Ohio State University Wexner Medical Center) The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Scientists identify protein markers related to the most common form of leukemia
(Wiley) Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. New research published in the Journal of Leukocyte Biology reveals that certain protein markers may indicate which patients have stable forms of CLL and which have more aggressive types. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Zydus Cadila gets tentative nod from USFDA to market cancer drug
"Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia," Zydus Cadila said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 21, 2021 Category: Pharmaceuticals Source Type: news

New discoveries reveal how acute myeloid leukemia walks line between growth and cell death
(University of Chicago) Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a study published in Molecular Cell on July 20, 2021. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2021 Category: International Medicine & Public Health Source Type: news

Ficlatuzumab plus chemotherapy may benefit patients with relapsed/refractory AML
(American Association for Cancer Research) The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news

CDC advisers to consider additional coronavirus dose for immunocompromised patients
An advisory panel next week plans to focus on the 2 to 4 percent of U.S. adults who have suppressed immunity, a population that includes organ transplant recipients, people on cancer treatments and those living with rheumatologic conditions, HIV and leukemia. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - July 15, 2021 Category: Consumer Health News Authors: Lena H. Sun Source Type: news

MD Anderson research highlights for July 14, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising combination therapy for acute myeloid leukemia, understanding mechanisms driving resistance to PARP inhibitors, a therapeutic neoantigen vaccine to treat lung cancer, a novel treatment for triple-negative breast cancer and a new understanding of how telomeres may drive inflammatory bowel disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukemia and lymphoma
Hematology / Oncology News Burst FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukemia and lymphoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 12, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Oncotarget: Inhibitory effects of Tomivosertib in acute myeloid leukemia
(Impact Journals LLC) These Oncotarget findings demonstrate that Tomivosertib exhibits potent anti-leukemic properties on AML cells and support the development of clinical translational efforts involving the use of this drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: news

Can leukemia in children with Down syndrome be prevented?
(University Health Network) For the first time, Princess Margaret researchers have mapped out where and how leukemia begins and develops in infants with Down syndrome in preclinical models, paving the way to potentially prevent this cancer in the future. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2021 Category: Cancer & Oncology Source Type: news

Unraveling the mechanisms that create the individualized metabolism in leukemia
(Kumamoto University) Lysine-specific demethylase 1 (LSD1), an enzyme involved in gene expression, produces individualized metabolism depending on the type of acute myeloid leukemia cells. Cancer cells have a unique ability to metabolize substances differently from normal cells, and this ability is considered to be a promising therapeutic target. New findings may contribute to the safe and effective use of LSD1 inhibitors as potential anticancer agents, and to the development of highly specific treatments for various leukemia types. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 5, 2021 Category: Cancer & Oncology Source Type: news

FDA Approves New Asparaginase Product for Leukemia FDA Approves New Asparaginase Product for Leukemia
The new recombinant product, Rylaze, is approved for use in patients who have developed hypersensitivity to asparaginase derived from E coli.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

MD Anderson research highlights for June 30, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include expanded use of a targeted therapy for a new group of patients with leukemia, molecular studies yielding novel cancer therapeutic targets, insights into radiation therapy resistance and a community intervention to reduce cervical cancer rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 30, 2021 Category: Cancer & Oncology Source Type: news

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 30, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 30, 2021 Category: Drugs & Pharmacology Source Type: news

2021 ABCD Young Scientist Award feline health
2021 Young Scientist Award winners announcedYoung veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their outstanding work into feline SARS-CoV-2 infections and feline leukaemia virus, respectivelyBoehringer Ingelheim has been sponsoring the award since 2008 to help foster talent development in the feline health research communityAward represents important collaboration between Boehringer Ingelheim and the Advisory Board on Cat Diseases (ABCD) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 28, 2021 Category: Research Source Type: news

Two studies by CU Cancer Center researchers explore link between inflammation and leukemia
(University of Colorado Anschutz Medical Campus) Two recent collaborative publications by CU Cancer Center members Eric Pietras, Ph.D. and James DeGregori, Ph.D., provide insights into how chronic inflammation can serve as a key factor in the development of leukemia and other blood cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 28, 2021 Category: International Medicine & Public Health Source Type: news

CU Cancer Center researcher studies oil & gas exposure effect on childhood leukemia risk
(University of Colorado Anschutz Medical Campus) A pilot study of childhood leukemia patients living near Colorado's oil and gas drilling sites recently led to an American Cancer Society (ACS) grant award for CU Cancer Center member Lisa McKenzie PhD, MPH. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 28, 2021 Category: International Medicine & Public Health Source Type: news

Hypomethylating Agents in Children With Relapsed/Refractory AML Hypomethylating Agents in Children With Relapsed/Refractory AML
Hypomethylating agents can serve as a bridge to transplant for children and young adults with relapsed or refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 25, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Novel risk score for predicting blood cancer relapse
(Cactus Communications) Several patients suffering from leukemia, who have undergone stem cell transplantation, are at a risk of relapse, owing to varied reasons. Before the inevitable, what if it is possible to predict this situation, and take appropriate medical measures? A group of researchers in China appear to have solved this challenge by developing a novel risk score for leukemia relapse prediction, according to a study published in Chinese Medical Journal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 24, 2021 Category: International Medicine & Public Health Source Type: news

Ibrutinib + Venetoclax Promising for Chronic Lymphocytic Leukemia
WEDNESDAY, June 23, 2021 -- Combination therapy with ibrutinib and venetoclax seems beneficial for patients with previously untreated chronic lymphocytic leukemia (CLL), according to a study published online June 10 in JAMA Oncology. Nitin Jain,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 23, 2021 Category: Pharmaceuticals Source Type: news

Autophagy in Hematological Malignancies Autophagy in Hematological Malignancies
This review examines the autophagy pathway and its role in the development of hematological malignancies, with a focus on myeloid and lymphoid leukemia and lymphoma.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news